Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Super-Curcumin is a proprietary dietary supplement formulation developed by American Finest Inc., consisting of a standardized extract of *Curcuma longa* known as Curcumin C3 Complex combined with BioPerine, a standardized extract of black pepper (*Piper nigrum*). Curcumin C3 Complex contains three main curcuminoids: curcumin, demethoxycurcumin, and bisdemethoxycurcumin. BioPerine contains piperine, which acts as a bioavailability enhancer by inhibiting metabolic pathways such as glucuronidation in the liver and intestinal wall, significantly increasing the systemic absorption of curcumin. Clinically, Super-Curcumin has been investigated as an adjunctive treatment for schizophrenia and schizoaffective disorder. Its therapeutic potential is attributed to its anti-inflammatory effects through the inhibition of inducible nitric oxide synthase (iNOS) and its ability to act as an epigenetic modulator by inhibiting histone acetyltransferases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Super-Curcumin.